Research ExplorerPublicationsSuccessful use of a left ventricular apical access and closu...

Successful use of a left ventricular apical access and closure device for second-generation transapical aortic valve implantation

Standard

Successful use of a left ventricular apical access and closure device for second-generation transapical aortic valve implantation. / Conradi, Lenard; Seiffert, Moritz; Shimamura, Kazuo; Schirmer, Johannes; Blankenberg, Stefan; Reichenspurner, Hermann; Diemert, Patrick; Treede, Hendrik.

In: THORAC CARDIOV SURG, Vol. 62, No. 6, 09.2014, p. 498-502.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Conradi, L, Seiffert, M, Shimamura, K, Schirmer, J, Blankenberg, S, Reichenspurner, H, Diemert, P & Treede, H 2014, 'Successful use of a left ventricular apical access and closure device for second-generation transapical aortic valve implantation', THORAC CARDIOV SURG, vol. 62, no. 6, pp. 498-502. https://doi.org/10.1055/s-0034-1381743

APA

Conradi, L., Seiffert, M., Shimamura, K., Schirmer, J., Blankenberg, S., Reichenspurner, H., Diemert, P., & Treede, H. (2014). Successful use of a left ventricular apical access and closure device for second-generation transapical aortic valve implantation. THORAC CARDIOV SURG, 62(6), 498-502. https://doi.org/10.1055/s-0034-1381743

Vancouver

Conradi L, Seiffert M, Shimamura K, Schirmer J, Blankenberg S, Reichenspurner H et al. Successful use of a left ventricular apical access and closure device for second-generation transapical aortic valve implantation. THORAC CARDIOV SURG. 2014 Sep;62(6):498-502. https://doi.org/10.1055/s-0034-1381743

Bibtex

@article{c4bef0e0f39a4433b8468373e017af9c,
title = "Successful use of a left ventricular apical access and closure device for second-generation transapical aortic valve implantation",
abstract = "BACKGROUND: Transcatheter aortic valve implantation (TAVI) has become routine for the treatment of high-risk patients with aortic stenosis. We assessed safety and feasibility of a left ventricular apical access and closure device combined with second-generation transapical (TA) TAVI transcatheter heart valves (THV).METHODS AND RESULTS: Three elderly, comorbid patients (logEuroSCORE I 13.0-31.1%) received transapical aortic valve implantation (TA-AVI) via the Apica ASC device (Apica Cardiovascular Ltd., Galway, Ireland) using second-generation THV (Medtronic Engager [Medtronic 3F Therapeutics, Santa Ana, California, United States], JenaValve [JenaValve Technology GmbH, Munich, Germany], Symetis Acurate [Symetis S.A., Ecublens, Switzerland]). Access was gained using a non-rib-spreading technique and a novel access and closure device. THV deployment was successful with excellent hemodynamic outcome (no PVL, n = 2; trace PVL, n = 1; mean transvalvular gradients, 5-19 mm Hg) and complete apical hemostasis. No periprocedural major adverse events occurred and Valve Academic Research Consortium-2-defined composite end point of device success was met in all cases.CONCLUSION: Safety and feasibility of TA-AVI using the ASC device with second-generation THV was demonstrated. Combining latest available technology is a major step toward improved functional outcome and decreased surgical trauma in TA-AVI. Potentially, technical enhancements may eventually pave the way toward a fully percutaneous TA-AVI procedure.",
keywords = "Aged, 80 and over, Aortic Valve/physiopathology, Aortic Valve Stenosis/diagnosis, Cardiac Catheterization/adverse effects, Feasibility Studies, Female, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation/adverse effects, Hemodynamics, Hemorrhage/etiology, Hemostatic Techniques/adverse effects, Humans, Male, Prosthesis Design, Punctures, Severity of Illness Index, Treatment Outcome",
author = "Lenard Conradi and Moritz Seiffert and Kazuo Shimamura and Johannes Schirmer and Stefan Blankenberg and Hermann Reichenspurner and Patrick Diemert and Hendrik Treede",
note = "Georg Thieme Verlag KG Stuttgart · New York.",
year = "2014",
month = sep,
doi = "10.1055/s-0034-1381743",
language = "English",
volume = "62",
pages = "498--502",
journal = "THORAC CARDIOV SURG",
issn = "0171-6425",
publisher = "Georg Thieme Verlag KG",
number = "6",

}

RIS

TY - JOUR

T1 - Successful use of a left ventricular apical access and closure device for second-generation transapical aortic valve implantation

AU - Conradi, Lenard

AU - Seiffert, Moritz

AU - Shimamura, Kazuo

AU - Schirmer, Johannes

AU - Blankenberg, Stefan

AU - Reichenspurner, Hermann

AU - Diemert, Patrick

AU - Treede, Hendrik

N1 - Georg Thieme Verlag KG Stuttgart · New York.

PY - 2014/9

Y1 - 2014/9

N2 - BACKGROUND: Transcatheter aortic valve implantation (TAVI) has become routine for the treatment of high-risk patients with aortic stenosis. We assessed safety and feasibility of a left ventricular apical access and closure device combined with second-generation transapical (TA) TAVI transcatheter heart valves (THV).METHODS AND RESULTS: Three elderly, comorbid patients (logEuroSCORE I 13.0-31.1%) received transapical aortic valve implantation (TA-AVI) via the Apica ASC device (Apica Cardiovascular Ltd., Galway, Ireland) using second-generation THV (Medtronic Engager [Medtronic 3F Therapeutics, Santa Ana, California, United States], JenaValve [JenaValve Technology GmbH, Munich, Germany], Symetis Acurate [Symetis S.A., Ecublens, Switzerland]). Access was gained using a non-rib-spreading technique and a novel access and closure device. THV deployment was successful with excellent hemodynamic outcome (no PVL, n = 2; trace PVL, n = 1; mean transvalvular gradients, 5-19 mm Hg) and complete apical hemostasis. No periprocedural major adverse events occurred and Valve Academic Research Consortium-2-defined composite end point of device success was met in all cases.CONCLUSION: Safety and feasibility of TA-AVI using the ASC device with second-generation THV was demonstrated. Combining latest available technology is a major step toward improved functional outcome and decreased surgical trauma in TA-AVI. Potentially, technical enhancements may eventually pave the way toward a fully percutaneous TA-AVI procedure.

AB - BACKGROUND: Transcatheter aortic valve implantation (TAVI) has become routine for the treatment of high-risk patients with aortic stenosis. We assessed safety and feasibility of a left ventricular apical access and closure device combined with second-generation transapical (TA) TAVI transcatheter heart valves (THV).METHODS AND RESULTS: Three elderly, comorbid patients (logEuroSCORE I 13.0-31.1%) received transapical aortic valve implantation (TA-AVI) via the Apica ASC device (Apica Cardiovascular Ltd., Galway, Ireland) using second-generation THV (Medtronic Engager [Medtronic 3F Therapeutics, Santa Ana, California, United States], JenaValve [JenaValve Technology GmbH, Munich, Germany], Symetis Acurate [Symetis S.A., Ecublens, Switzerland]). Access was gained using a non-rib-spreading technique and a novel access and closure device. THV deployment was successful with excellent hemodynamic outcome (no PVL, n = 2; trace PVL, n = 1; mean transvalvular gradients, 5-19 mm Hg) and complete apical hemostasis. No periprocedural major adverse events occurred and Valve Academic Research Consortium-2-defined composite end point of device success was met in all cases.CONCLUSION: Safety and feasibility of TA-AVI using the ASC device with second-generation THV was demonstrated. Combining latest available technology is a major step toward improved functional outcome and decreased surgical trauma in TA-AVI. Potentially, technical enhancements may eventually pave the way toward a fully percutaneous TA-AVI procedure.

KW - Aged, 80 and over

KW - Aortic Valve/physiopathology

KW - Aortic Valve Stenosis/diagnosis

KW - Cardiac Catheterization/adverse effects

KW - Feasibility Studies

KW - Female

KW - Heart Valve Prosthesis

KW - Heart Valve Prosthesis Implantation/adverse effects

KW - Hemodynamics

KW - Hemorrhage/etiology

KW - Hemostatic Techniques/adverse effects

KW - Humans

KW - Male

KW - Prosthesis Design

KW - Punctures

KW - Severity of Illness Index

KW - Treatment Outcome

U2 - 10.1055/s-0034-1381743

DO - 10.1055/s-0034-1381743

M3 - SCORING: Journal article

C2 - 24911901

VL - 62

SP - 498

EP - 502

JO - THORAC CARDIOV SURG

JF - THORAC CARDIOV SURG

SN - 0171-6425

IS - 6

ER -